Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates

Over the last four quarters, the company has surpassed consensus EPS estimates three times. Capricor, which belongs to the Zacks Medical - Products industry, posted revenues of $4.91 million for the quarter ended March 2024, missing the Zacks Consensus Estimate by 50.93$2.99 million. The company has topped consensus revenue estimates two times over the last four quarters. Capricor Therapeutics (CAPR) came out with a quarterly loss of $0.31 per share versus the Zacks ...